Interpace Biosciences®, Inc. Annual report pursuant to Section 13 and 15(d)

Supplemental Cash Flow Information (Tables)

12 Months Ended

Dec. 31, 2019

	For The Years Ended December 31,
	2019			2018
Net cash used in operating activities of discontinued operations	$	(30	)	$	(361	)

Net cash provided by investing activities of discontinued operations	$	-		$	-

Supplemental Disclosure of Other Cash Flow Information

(in thousands)

Cash paid for taxes		$	227			$	324
Cash paid for interest		$	170			$	-

Supplemental Disclosures of Non Cash Activities

(in thousands)

	Years Ended
	December 31,
	2019		2018
Operating
Adoption of ASC 606	$	-	$	2,500
Prepaid stock grants issued to vendors	$	-	$	497
Adoption of ASC 842 - right of use asset	$	2,449	$	-
Adoption of ASC 842 - operating lease liability	$	2,536	$	-

Financing

Accrued financing costs	$	342	$	-
Accrued preferred dividends	$	429	$	-